GENEWIZ, Inc. Announces European Expansion & Appointment of Biserka Bacic-Toplek, Sales Executive

South Plainfield, NJ and Langen, DE -- October 22, 2013 -- Leading global genomics service provider, GENEWIZ, Inc., today announced expansion of its European operations with the introduction of GENEWIZ Germany. Biserka Bacic-Toplek has been appointed as Sales Executive to lead GENEWIZ Germany business operations. 

Having established European operations in 2011, GENEWIZ has been providing reliable, high quality genomic services to the global scientific community since 1999. The GENEWIZ portfolio of products and services include gene synthesis; DNA sequencing (Sanger & next generation sequencing); molecular biology; bioinformatics; and GxP/CLIA regulatory-complaint services. Accreditation from the College of American Pathologists (CAP) enables GENEWIZ to provide clinical genomic services, such as biologic drug and cell bank characterization testing, clinical trial investigations, and clinical diagnostic testing, to provide clinically relevant genomic information for physicians, pathologists, and clinical researchers.

With a constant commitment to quality, GENEWIZ maintains International Organization for Standardization (ISO) 9001:2008 Certification for Quality Management, a voluntary certification recognizing operational excellence and quality standards. Combining quality and expertise, GENEWIZ custom gene synthesis services offer efficient, accurate, and cost-effective solutions for synthetic biology researchers in Germany and throughout Europe. 

"As a global service provider, we have the resources and capabilities to deliver reliable, optimized results. Now, with the introduction of GENEWIZ Germany and appointment of Biserka Bacic-Toplek, we are able to offer enhanced support for local researchers to enrich their overall GENEWIZ experience," stated Steve Manobianco, Vice President, Global Sales & Marketing. 

"Due to our extensive experience designing complex constructs, such as difficult templates, highly repetitive, AT-rich, and GC-rich DNA, as well as our ability to codon-optimize sequences, GENEWIZ can deliver custom projects designed to meet any research specifications," asserted Andre Kotze, European Business Development Manager. "A brilliant example of this is the recent synthesis of the H7N9 influenza virus, which GENEWIZ delivered in record time."

"Based in Langen, the opening of GENEWIZ Germany demonstrates our dedication to serving the growing global scientific community, as well as our constant commitment to the advancement of life science research through scalable solutions and specialized expertise," remarked Manobianco.

About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions. 

Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.